Johnson & Johnson pauses U.S. Varipulse cases to investigate neurovascular events. The FDA-approved device integrates PFA ...

Johnson & Johnson said on Wednesday it temporarily paused the rollout of its Varipulse heart device in the United States as ...

The temporary pause follows reports of four cases of neurovascular events in the US external evaluation study.

Johnson & Johnson halted the limited rollout of its Varipulse pulsed field ablation system on Jan. 5 to “investigate the root causes of four reported neurovascular events in the U.S. external ...

J&J's MedTech unit pauses all cases of the Varipulse PFA system as part of an external evaluation. Stock dips.

After a busy 2024, experts called out competition in soft tissue robotics, uncertainty from a Trump White House and continued success for pulsed field ablation as trends to watch this year.

Johnson & Johnson announced the nipocalimab Biologics License Application received Priority Review designation from the U.S Food and Drug ...

Wells Fargo analyst Larry Biegelsen maintained a Hold rating on Johnson & Johnson (JNJ – Research Report) yesterday and set a price target ...

Johnson & Johnson has won Food and Drug Administration priority review for its application seeking approval of nipocalimab in certain patients with generalized myasthenia gravis.

Biologics License Application acceptance supported by results from the Phase 3 Vivacity-MG3 study Results demonstrate sustained disease control over 24 weeks in a broad ...

Johnson & Johnson (NYSE:JNJ) has received Priority Review designation from the FDA for the Biologics License Application for ...

Political leaders have shunned the Alternative for Germany. But on his social media platform X, Mr. Musk is pitching the party as mainstream. By Jim Tankersley Pierre Poilievre, the Conservative ...